.Merck defeats profits expectations, rears purchases outlook on solid requirement for top medications like Keytruda CNBCMerck & Co. (MRK United States) Defeats Profit Projections as Keytruda Purchases Growth BloombergMerck Stock: Pharma Titan Posts Strong Outcomes, But Outlook Drops Short Real estate investor's Service DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck beats income and also sales requirements amid Keytruda strength, however gives blended full-year outlook MarketWatch.